Celgene (CELG) - Label Expansion of Marketed Product and Newly Drug launches + Maturing Pipeline = Long Term Gain
CELG’s Maturing pipeline through its own proprietary compounds and acquisition/in-licensing should keep the momentum positively in coming years. New launches – POMALYST (L, Pomalidomide, RRMM), Apremilast (PR, Psoriasis, PsA), and label and geographic expansion of marketed products – Revlimid, Vidaza, and ABRAXANE (L, mBC, NSCLC; R – pancreatic cancer, PDUFA: Sept. 21, 2013) should sustain the growth for long term. CELG has recently raised $1.5b in senior notes strengthening its balance sheet and continues it buyback plans ($3b announced in June 2013). We expect ... For more detail please read our report on Celgene released on 2nd Sept. 2013, titled, "Label Expansion of Marketed Product and Newly Drug launches + Maturing Pipeline = Long Term Gain".
More Publications
Incyte - Label Expansion + Upcoming Milestones Sufficient Reason to Remain Invested for Long Term!
US$ 140.00
June 2013
9 pages
CELGENE - Prospects Bright beyond Revlimid in MM - New Products + Label Expansion
US$ 140.00
January 2013
6 pages
Niche Products, Label expansion and No Competition - Growth Drivers
US$ 140.00
July 2011
7 pages
Acorda Therapeutics - Pipeline and Label Expansion of AMPYRA- Drivers of Growth
US$ 140.00
June 2013
3 pages
ALEXION - Great Expectations From Label Expansion
US$ 140.00
September 2011
4 pages
